Q3’25 Investor Survey: What are Investors Most Concerned About? Post published:October 23, 2025 Post category:Analysis/News/Pα+
Q3’25 Survey: What are Psychedelics Investors Excited About? Post published:October 21, 2025 Post category:Analysis/News/Pα+
Q2 2025: Oregon Psilocybin Services Update Post published:October 10, 2025 Post category:Analysis/News/Pα+
Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study Post published:September 22, 2025 Post category:Analysis/News/Pα+
UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence Post published:September 19, 2025 Post category:Analysis/News/Pα+
Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts Post published:September 16, 2025 Post category:2024 Year in Review/Analysis
Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos Post published:September 8, 2025 Post category:Analysis/News/Pα+